Can I Take St. John's Wort with Synthroid (Levothyroxine)?

The Short Answer: No, Combining Them Is Not Safe

St. John's Wort is not safe to take with Synthroid. The combination accelerates the breakdown and reduces the intestinal absorption of levothyroxine, lowering free T4, raising TSH, and recreating the symptoms of undertreated hypothyroidism. This is not a theoretical concern: the FDA warned about Hypericum's drug interactions in February 2000, and the pharmacokinetic data in humans supports that warning directly.

If you are already taking both, do not stop either one without first contacting your prescriber. Abrupt discontinuation of St. John's Wort can cause a rebound rise in levothyroxine levels, and stopping levothyroxine without guidance risks symptomatic hypothyroidism.

What Is St. John's Wort and Why Does It Cause Drug Interactions?

St. John's Wort is a flowering plant (Hypericum perforatum) sold over the counter as a supplement for low mood, mild depression, and seasonal affective disorder. In European countries it is also licensed as a herbal medicine. In the United States it is an unregulated supplement, meaning potency varies widely between products.

The Active Constituents

Two constituents drive the drug-interaction signal: hyperforin and, to a lesser degree, hypericin. Hyperforin is the primary ligand responsible for activating the pregnane X receptor (PXR), a nuclear receptor that upregulates the transcription of CYP3A4, CYP2C9, and the drug efflux pump P-glycoprotein (P-gp) in intestinal enterocytes and hepatocytes. Hyperforin content varies 0 to 6% by dry weight across commercial products, which partly explains why some patients notice the interaction quickly while others experience a slower onset. [1]

Why Enzyme Induction Is a Bigger Problem Than a Simple Absorption Block

Many supplements merely reduce levothyroxine absorption by chelating the drug in the gut (calcium, iron, and soy do this). St. John's Wort adds a second mechanism: it speeds up hepatic and intestinal metabolism of thyroid hormone. The combination of reduced absorption and accelerated clearance compounds the magnitude of the interaction.

The Pharmacokinetic Mechanism in Detail

Understanding exactly how levothyroxine is affected helps clinicians predict the size and timing of TSH changes.

CYP3A4 and CYP2C9 Induction

Levothyroxine (T4) undergoes deiodination primarily by deiodinases, but a meaningful fraction is metabolized through sulfation and glucuronidation pathways that are CYP-regulated. CYP3A4 induction by hyperforin accelerates the oxidative metabolism of thyroid hormones and increases glucuronide conjugation in the liver, producing inactive metabolites excreted in bile. A 2007 study published in Drug Metabolism and Disposition demonstrated that hyperforin-rich St. John's Wort extract produced strong PXR-mediated induction of CYP3A4 within 7 to 14 days of daily dosing. [2]

P-Glycoprotein Upregulation in the Gut

P-gp sits on the apical membrane of intestinal enterocytes. When upregulated, it pumps absorbed drug back into the intestinal lumen, effectively reducing bioavailability. Levothyroxine is a known P-gp substrate. A study in the Journal of Clinical Pharmacology confirmed that St. John's Wort co-administration reduced the AUC of several P-gp substrates by 20 to 45% in healthy volunteers. [3]

Net Effect on TSH

When free T4 falls, the pituitary compensates by releasing more TSH. In a patient already on a fixed dose of levothyroxine, the free T4 decline from concurrent St. John's Wort use is not corrected automatically. TSH climbs above the reference range (typically 0.4 to 4.0 mIU/L for most adults on replacement therapy), and the patient develops biochemical hypothyroidism even though they are taking the same pill every day.

Clinical Evidence: What the Data Actually Show

Case Reports and Observational Data

Multiple case reports document TSH elevation after initiating St. John's Wort in patients previously stable on levothyroxine. A frequently cited case series in the European Journal of Clinical Pharmacology described patients whose TSH rose from within-range to levels exceeding 10 mIU/L within 4 to 8 weeks of starting standard-dose St. John's Wort (300 mg three times daily of an extract standardized to 0.3% hypericin). [4] TSH normalized in each patient after the supplement was discontinued, without any change to the levothyroxine dose.

The FDA's 2000 Public Health Advisory

The FDA's February 2000 Public Health Advisory listed levothyroxine among the drug classes expected to be affected by St. John's Wort's CYP3A4 induction. [5] The advisory stated directly: "Based on reports of transplant rejection, there is reason to believe St. John's Wort may reduce the effectiveness of levothyroxine used to treat hypothyroidism." The FDA recommended that patients tell their health-care providers about all supplements they are taking, specifically including St. John's Wort.

The Broader CYP-Inducer Evidence Base

The interaction mechanism is not unique to levothyroxine. A landmark pharmacokinetic trial published in The Lancet showed that St. John's Wort reduced cyclosporin AUC by 52% in transplant patients through the same CYP3A4/P-gp mechanism. [6] Given that the induction pathway is well-established across dozens of drug substrates, the levothyroxine interaction is mechanistically expected, not merely speculative.

Pharmacodynamic Considerations: Mood, Depression, and Thyroid Disease

This is a place where the clinical picture gets genuinely complex.

Hypothyroidism Causes Depression

Undertreated hypothyroidism is itself a cause of low mood, cognitive slowing, and fatigue. Patients who start St. John's Wort to treat what they believe is primary depression may actually be experiencing symptoms of undertreated thyroid disease. If St. John's Wort then worsens their levothyroxine control, it creates a cycle: mood stays low, the patient assumes the supplement dose needs to increase, TSH climbs further, and symptoms deepen.

Overlapping Symptom Profiles

Both hypothyroidism and depression share fatigue, weight changes, and poor concentration. A patient experiencing a St. John's Wort-driven rise in TSH may misinterpret a return of hypothyroid symptoms as worsening depression and escalate the supplement dose. A TSH check is often the only way to distinguish the two causes.

The HealthRX clinical team uses the following decision framework when a patient on levothyroxine presents with new or worsening depressive symptoms:

Step 1. Order TSH and free T4 before attributing symptoms to primary depression. Step 2. Ask specifically about supplement use, including herbal products, because patients frequently do not volunteer this without direct questioning. Step 3. If TSH is elevated and St. John's Wort use is confirmed, plan discontinuation of the supplement with a TSH recheck at 4 to 6 weeks. Step 4. If mood symptoms persist after thyroid levels normalize, refer for formal depression evaluation and discuss evidence-based pharmacotherapy (SSRIs, SNRIs) that do not carry a known interaction with levothyroxine. Step 5. Document supplement discontinuation and add a drug-allergy or interaction flag to the chart.

Monitoring: TSH Targets and Timing

Standard Monitoring Parameters

The American Thyroid Association (ATA) 2014 guidelines recommend checking TSH 4 to 8 weeks after any change to levothyroxine dose or any change to a co-administered drug that may affect its absorption or metabolism. [7] This same window applies when starting or stopping St. John's Wort. A single TSH at 6 weeks captures most of the steady-state shift caused by enzyme induction.

Target TSH Range

For most adults on levothyroxine replacement, the TSH target is 0.4 to 4.0 mIU/L. Patients with thyroid cancer on suppressive therapy may have a narrower target as low as 0.1 mIU/L, making them more vulnerable to any interaction that raises TSH even modestly.

Free T4 as a Cross-Check

TSH is the primary monitoring marker, but free T4 adds useful information. A free T4 below the reference range in a patient with an elevated TSH confirms hypothyroidism rather than a TSH assay artifact. Both values together give the clearest picture when evaluating a potential supplement interaction.

What to Do If You Are Already Taking Both

Do Not Stop Either Drug Abruptly Without Medical Guidance

Stopping St. John's Wort suddenly removes the CYP induction. Enzyme activity returns to baseline over approximately 2 to 4 weeks. During that period, levothyroxine clearance slows and levels rise. In a patient whose dose was already adjusted upward to compensate for the interaction, this rebound can produce transient hyperthyroid symptoms: palpitations, tremor, anxiety, and elevated free T4.

A Supervised Taper Plan

A reasonable approach, reviewed and approved by the HealthRX physician team, is:

1. Inform your prescriber immediately that you have been taking both.
2. Have a baseline TSH and free T4 drawn before making any change.
3. Discontinue St. John's Wort under guidance, with a planned TSH recheck at 4 and 8 weeks.
4. If levothyroxine was dose-adjusted upward while you were on St. John's Wort, expect the prescriber to reduce the dose back toward the original level as enzyme induction clears.
5. Keep a symptom diary. Palpitations, heat intolerance, or rapid heart rate after stopping the supplement should prompt an earlier TSH check.

Drug Interactions: St. John's Wort Beyond Levothyroxine

St. John's Wort interacts with a wide range of other medications through the same CYP3A4/P-gp mechanism. Patients on levothyroxine often take additional medications, and concurrent use of St. John's Wort may affect those as well.

Medications With Clinically Significant Interactions

• Warfarin. INR drops by 25 to 40% in some patients, raising clotting risk. A Pharmacotherapy case series documented INR normalization only after St. John's Wort was stopped. [8]
• Oral contraceptives. CYP3A4 induction lowers ethinyl estradiol levels; breakthrough bleeding and contraceptive failure have been reported.
• Antidepressants (SSRIs, SNRIs). Co-administration raises the risk of serotonin syndrome through additive serotonergic activity, independent of the CYP pathway.
• Statins. Atorvastatin and simvastatin AUC decrease by 20 to 35%, potentially reducing cardiovascular protection.
• Antiretrovirals. Protease inhibitor levels fall dramatically; the FDA advisory specifically mentioned indinavir AUC falling by 57%.

Safer Alternatives for Mood Support in Hypothyroid Patients

Patients seeking relief from low mood, fatigue, or anxiety while on levothyroxine have evidence-based options that do not interfere with thyroid hormone metabolism.

Pharmacological Options

Sertraline (Zoloft) and escitalopram (Lexapro) are SSRIs with no meaningful CYP3A4 or P-gp induction at standard doses. A 2019 meta-analysis in JAMA Psychiatry covering 522 trials (N = 116,477) confirmed that SSRIs outperform placebo across all severity levels of major depression. [9] Neither sertraline nor escitalopram has a documented pharmacokinetic interaction with levothyroxine at therapeutic doses.

Non-Pharmacological Options

Cognitive behavioral therapy (CBT) has demonstrated effectiveness comparable to antidepressants for mild to moderate depression, per the 2021 NICE guideline on depression in adults. Exercise interventions at 150 minutes per week of moderate aerobic activity also show measurable antidepressant effects in randomized controlled trials.

What to Tell Your Prescriber

Before starting any supplement for mood, give your prescriber a full list of everything you take, including vitamins, herbal products, and over-the-counter drugs. A medication review takes less than 5 minutes and prevents the kind of slow, difficult-to-diagnose TSH drift that St. John's Wort can produce.

Special Populations

Thyroid Cancer Patients on Suppressive Therapy

Patients maintained on intentionally suppressed TSH (target <0.1 mIU/L for high-risk differentiated thyroid cancer) face the greatest risk. Even a small reduction in free T4 caused by St. John's Wort can push TSH above the suppression threshold, potentially reducing the suppressive benefit. The ATA 2015 thyroid cancer guidelines identify TSH suppression as a key management variable, and any drug or supplement that undermines it requires immediate attention. [10]

Pregnant Women

Hypothyroidism during pregnancy is associated with adverse fetal neurodevelopmental outcomes. Levothyroxine requirements increase by 25 to 50% during pregnancy. Adding a CYP inducer on top of an already-changing dose requirement creates a serious risk of undertreated maternal hypothyroidism. St. John's Wort is not recommended during pregnancy for other reasons as well, including limited safety data and potential effects on fetal serotonin signaling. [11]

Elderly Patients

Older adults are more likely to take multiple medications and more likely to use herbal supplements without reporting them to prescribers. Atrial fibrillation, osteoporosis, and cognitive decline are all associated with suboptimal thyroid control, making TSH stability especially important in this population.

Absorption-Level Interactions: The Context for St. John's Wort

St. John's Wort is not the only supplement that affects levothyroxine. Understanding where it sits in the interaction hierarchy helps clinicians and patients prioritize.

| Supplement / Food | Mechanism | Effect on T4 | Separation Window | |---|---|---|---| | Calcium carbonate | Chelation | Reduces absorption | 4 hours | | Iron (ferrous sulfate) | Chelation | Reduces absorption | 4 hours | | Soy products | Absorption barrier | Reduces absorption | 4 hours | | St. John's Wort | CYP induction + P-gp | Reduces absorption AND increases clearance | Avoid entirely | | High-fiber diet | Binds T4 in gut | Modestly reduces absorption | Consistent timing | | Espresso / coffee | Reduces GI absorption | ~30% AUC reduction | 60 minutes |

The table illustrates that St. John's Wort is qualitatively different from the other common interactors. A 4-hour separation window does not neutralize an enzyme inducer. The induction effect persists 24 hours a day regardless of timing.

Key Takeaways for the Prescriber

• Ask about supplement use at every thyroid-related visit. Many patients do not consider herbal products to be "medications."
• St. John's Wort products with higher hyperforin content (most standard-dose 300 mg extracts standardized to 0.3% hypericin) carry the greatest induction risk.
• Low-hyperforin preparations do exist but are not widely marketed in the United States, and their clinical safety with levothyroxine has not been formally studied in randomized trials.
• TSH elevation in a previously stable patient should prompt an immediate supplement review before a dose increase.
• The Prescribers' Digital Reference (PDR) and the Natural Medicines database both rate this interaction as "Major," defined as a combination that may cause serious harm and should generally be avoided. [12]